Top Markets
Coin of the day
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
Rang in aandelen #39567
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Aandeelprijs
$0.003084
Marktkapitalisatie
$434.03K
Verandering (1 dag)
-7.14%
Verandering (1 jaar)
-89.24%
Land
BE
Handel Oxurion N.V. (OXUR)

Categorie

Dividendrendementgeschiedenis voor Oxurion N.V. (OXUR)
Het dividendrendement (TTM) van Oxurion N.V. (aandelsymbool: OXUR) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Oxurion N.V. (OXUR) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten